{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:22:50Z","timestamp":1789906970549,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.radonc.2015.05.016","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T03:47:46Z","timestamp":1434167266000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial"],"prefix":"10.1016","volume":"115","clinical-trial-number":[{"clinical-trial-number":"nct00193856","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"James W.","family":"Denham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Steigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel A.","family":"Spry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Duchesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keen-Hun","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirdosh Kumar","family":"Gogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suki","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrick","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kearvell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Delahunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Oldmeadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Holliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.05.016_b0005","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S1470-2045(12)70423-0","article-title":"Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial","volume":"13","author":"Denham","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0010","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2012.09.018","article-title":"Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer","volume":"105","author":"Denham","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1754-9485.2009.02047.x","article-title":"Comprehensive Australasian multicentre dosimetric intercomparison: issues, logistics and recommendations","volume":"53","author":"Ebert","year":"2009","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0020","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1118\/1.3626484","article-title":"Dosimetric intercomparison for multicentre clinical trials using a patient-based anatomic pelvic phantom","volume":"38","author":"Ebert","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0025","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1118\/1.3626573","article-title":"Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison","volume":"38","author":"Harrison","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2013.03.025","article-title":"Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer","volume":"107","author":"Denham","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1754-9485.12025","article-title":"Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 \u2018RADAR\u2019 trial","volume":"57","author":"Kearvell","year":"2013","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2007.11.013","article-title":"Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system","volume":"86","author":"Ebert","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0045","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0050","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","volume":"15","author":"Denham","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0055","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Statist Assoc"},{"key":"10.1016\/j.radonc.2015.05.016_b0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2007.06.029","article-title":"Dynamic contract-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy","volume":"70","author":"Haider","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.ijrobp.2010.01.006","article-title":"Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?","volume":"79","author":"Kuban","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0070","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of convention-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2015.05.016_b0075","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2004.05.033","article-title":"The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity","volume":"60","author":"Beckendorf","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0080","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0085","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(95)00063-5","article-title":"Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone","volume":"32","author":"Shipley","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.016_b0095","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","article-title":"Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumour control and distant metastases-free survival outcomes","volume":"60","author":"Zelefsky","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2015.05.016_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2010.02.022","article-title":"Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial","volume":"96","author":"Al-Mamgani","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0105","unstructured":"Smith MJ, Akhtar NH, Tagawa ST. The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer. Prostate Cancer. 2012;2012, Article ID 280278."},{"key":"10.1016\/j.radonc.2015.05.016_b0110","doi-asserted-by":"crossref","unstructured":"Morris W.J., Tyldesley S., Pai H.H., Halperin R., McKenzie M.R., Duncan G., et al. ASCENDE-RT\u2217: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol 33. 2015(suppl 7; abstr 3).","DOI":"10.1200\/jco.2015.33.7_suppl.3"},{"key":"10.1016\/j.radonc.2015.05.016_b0115","doi-asserted-by":"crossref","unstructured":"Rodda S., Tyldesley S., Morris W. GU and GI toxicity in ASCENDE-RT\u2217: a multicentre randomized trial of dose-escalated radiation for prostate cancer. 3rd ESTRO Forum (Abstract PD-0047); Barcelona 2015.","DOI":"10.1016\/S0167-8140(15)40047-7"},{"key":"10.1016\/j.radonc.2015.05.016_b0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.016_b0125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ijrobp.2012.07.006","article-title":"Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer","volume":"85","author":"Khor","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015002698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015002698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T21:46:03Z","timestamp":1566855963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015002698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0167814015002698"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.05.016","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}